0001209191-23-037320.txt : 20230615 0001209191-23-037320.hdr.sgml : 20230615 20230615161614 ACCESSION NUMBER: 0001209191-23-037320 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mathers Edward T CENTRAL INDEX KEY: 0001328625 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 231017546 MAIL ADDRESS: STREET 1: C/O MEDIMMUNE, INC. STREET 2: ONE MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-13 0 0001693011 Inozyme Pharma, Inc. INZY 0001328625 Mathers Edward T 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 1 0 0 0 0 Stock Option (right to buy) 6.18 2023-06-13 4 A 0 16000 0.00 A 2033-06-12 Common Stock 16000 16000 D The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. /s/ Louis Citron, attorney-in-fact 2023-06-15